676601-64-2

Upstream product

• 731825-97-1 3,4-difluorophenethyl 4-methylbenzenesulfonate 
• 179534-91-9 1-[2-(3,4-difluorophenyl)ethyl]piperazine 
• 286440-92-4 2-(3,4-difluorophenyl)ethan-1-ol 
• 61553-71-7 5H-pyrimido<5,4-b>indole-4-one 
• 97311-03-0 3-(dimethylamino-methyleneamino)-1H-indole-2-carboxylic acid ethyl ester 
• 87223-77-6 ethyl 3-amino-1H-indole-2-carboxylate 
• 658-93-5 (3,4-difluorophenyl)acetic acid 
• 731825-98-2 4-[2-(3,4-difluoro-phenyl)-ethyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 676601-63-1 1-chloro-6-nitro-9H-2,4,9-triazafluorene 
• 98792-02-0 4-chloro-5H-pyrimido<5,4-b>indole 
• 676601-59-5 1-{4-[2-(3,4-difluoro-phenyl)ethyl]-piperazin-1-yl}-6-nitro-9H-2,4,9-triaza-fluorene 

Relevant academic research and scientific papers

PYRROLOPYRIMIDINE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE (MDR)

A compound which is a pyrrolopyrimidine of formula (I) wherein R1 is selected from H, Cl-C6 alkyl which is unsubstituted or substituted, (CH2)nAr1, (CH2)pNR4R5, halogen and (CH2)pX; R2 is CH2)pArl; R3 is selected from H, Cl -C6 alkyl which is unsubstituted or substituted, (CH2)pZ and (CH2)pArl; P is an unsaturated 5, 6, or 7 membered carbocyclic or heterocyclic ring which is unsubstituted or substituted; R4 and R5 which are the same or different are selected from H, Cl -C6 alkyl which is unsubstituted or substituted, (CH2)nC3-C10 cycloalkyl, (CH2)nAr1 , and (CH2)nOR6, or R4 and R5 together with the nitrogen atom to which they are attached, form a saturated five or six membered nitrogen containing heterocyclic ring which may contain one extra heteroatom selected from 0, N and S and which is unsubstituted or substituted; R6 is selected from H, Cl -C6 alkyl which is unsubstituted or substituted, C3-C10 cycloalkyl, (CH2)nOC1-C6alkyl which is unsubstituted or substituted, (CH2)nO(CH2)nAr1 , (CH2)nCO2C1-C6,alkyl which is unsubstituted or substituted and (CH2)nAr1; X is selected from CN, azide, (CH2)nNHSO2R6 and (CH2)nNHCOR6; Z is selected from CN, CO2R6 and CONR4R5; Ar1 is the same or different when more than one is present within a given substituent group and is an unsaturated C6-C10 membered carbocylic group or an unsaturated 5-11 membered heterocycle, either of which is unsubstituted or substituted; p is an integer of 1 to 6; n is the same or different when more than one is present within a given substituent group and is 0 or an integer of 1 to 6; with the proviso that the pyrrolepyrimidine compound of formula (I) is other than 1-(4-benzyl-piperazin-1-yl)-9H-2,4,9-triaza-fluorene; and the pharmaceutically acceptable salts thereof, have activity as inhibitors of MRP (multidrug resistant protein) and may thus be used to modulate multidrug resistance, for instance in potentiating the cytotoxicity of a chemotherapeutic agent.

Design and Synthesis of New Templates Derived from Pyrrolopyrimidine as Selective Multidrug-Resistance-Associated Protein Inhibitors in Multidrug Resistance

In our continued effort to identify selective MRP1 modulators, we have developed two novel templates, 3 and 4, through rational drug design by identifying the key pharmacophore interaction at the 7-position of the pyrrolopyrimidine template 1. Further syn